![]() “iSpecimen continues to prioritize expanding its proprietary network and platform to ensure that researchers all over the world can easily obtain invaluable biospecimen samples necessary to propel their work forward.” Christopher Ianelli, M.D., Ph.D., iSpecimen Founder and CEO. “Adding Acutis to the iSpecimen Marketplace ecosystem enables the platform to become even more of a full-service, one-stop-shop for researchers looking to find highly sought-after samples and genetic information for their medical research,” added Dr. ![]() ![]() “Furthermore, our investment in personnel, technology and other essential resources allows us to provide high-quality, whole genome sequencing to iSpecimen for COVID-19 remnants, tumor samples, and other biospecimens of interest.” “This important initiative between Acutis and iSpecimen highlights our ongoing efforts to advance research in the areas of oncology and COVID-19 today,” said Jibreel Sarij, Acutis CEO. By offering sequencing services for specimens procured on iSpecimen’s platform, researchers can now identify desired samples and receive corresponding sequencing data from a single source instead of vetting and contracting with external sequencing service provider partners. Through the Acutis relationship, iSpecimen will now offer sequencing services to its research community that can help researchers better understand genetic mutations and their impact on diseases such as COVID-19 and cancer.Ĭancer and COVID-19 are currently the second and third leading causes of death in the U.S., respectively. As such, biospecimen samples for these diseases, along with corresponding sequencing data, remain in high demand among researchers who are working on the development of novel diagnostics and therapeutics that could lead to lifesaving medical interventions. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), a global online biospecimen marketplace that enables life scientists to search across a federated network of healthcare providers for biospecimens needed for medical research, today announced that it added Acutis Diagnostics (“Acutis”), a clinical diagnostics laboratory, to its platform as a laboratory services provider. “The new assay from Acutis Diagnostics will be designed to enable clinical researchers to work faster, and with a sound set of insights around their data, ultimately benefitting their current and future patients, as well as the industry as a whole.LEXINGTON, Mass., Ap(GLOBE NEWSWIRE) - iSpecimen Inc. ![]() SOPHiA GENETICS chief revenue officer Ken Freedman said: “Our work at SOPHiA GENETICS is focused on creating technology and solutions that make it easier for everyone to practice and benefit from data-driven medicine. Using SOPHiA GENETICS’ technology, the new assay from Acutis Diagnostics is expected to enhance clinical research and treatments for those with hereditary cancers. The technologies enable clinical researchers to accurately characterise the complex mutational landscape related to major hereditary cancer disorders. SOPHiA GENETICS said that its NGS-based hereditary cancer solutions use artificial intelligence (AI) and machine learning (ML) technologies, with its patented technologies. “Additionally, the test is to provide researchers with a robust set of data and insights to support clinical decision-making and future research.” The new test is said to support genomic screening for patient enrolment in cancer trials and for retrospective analyses to help explain clinical outcomes and drug target discovery.Īcutis Diagnostics chief scientific officer and executive vice president Abdel Halim said: “The use of SOPHiA DDM will help us quickly launch this new assay to aid clinical researchers in speeding up the process for launching select clinical oncology trials and ensuring the most appropriate patients are enrolled. The company will combine SOPHiA DDM for Hereditary Cancers Solution with its laboratory analysis technologies, to create the new assay. The cloud-native platform, dubbed SOPHiA DDM, is designed to analyse data and generate insights from complex multimodal data sets and different diagnostic modalities.Īcutis will develop the new genomic assay, based on its regulatory-approved lab-developed tests (LDTs) that support clinical trials, cancer research and treatment. ![]() (Credit: National Cancer Institute on Unsplash)Īcutis Diagnostics has selected SOPHiA GENETICS, a cloud-native healthcare software company, to use the latter’s platform for developing a new next-generation sequencing (NGS) test. Acutis will develop the new genomic assay, based on its approved lab-developed tests, by combining SOPHiA DDM for Hereditary Cancers Solution with its laboratory analysis technologiesĪcutis selects SOPHiA to create new NGS test. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |